B-cell Malignancies Clinical Trials

51 clinical trials for B-cell Malignancies across international registries, including 23 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. — RECRUITING · PHASE1
• An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies — RECRUITING · PHASE3
• CD19/70 Bi-specific CAR-T Cell Therapy — RECRUITING · PHASE1
• A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies — RECRUITING · PHASE1
• 4SCAR19U T Cells Targeting B Cell Malignancies — RECRUITING · PHASE1
• CD19/79b Bi-specific CAR-T Cell Therapy — RECRUITING · PHASE1
• Combination CAR-T Cell Therapy Targeting Hematological Malignancies — RECRUITING · PHASE1
• CD19/22 Bi-specific CAR-T Cell Therapy — RECRUITING · PHASE1
• A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies — RECRUITING · PHASE2
• Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies — RECRUITING · PHASE1
• A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies — RECRUITING · PHASE1
• JY231(JY231) Injection for the Treatment of R/R B-cell Malignancies — RECRUITING · NA
• Evaluation of SYS6005 in Patients With Advanced Malignant Tumor — RECRUITING · PHASE1
• A PHASE I TRIAL OF CLIC-2201 FOR THE TREATMENT OF RELAPSED/REFRACTORY B CELL MALIGNANCIES — RECRUITING · PHASE1
• A MODULAR PHASE I/II OPEN-LABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF AZD5492, A T CELL-ENGAGING ANTIBODY TARGETING CD20 IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES (TITANIUM) — RECRUITING · PHASE1
• Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients. — RECRUITING · PHASE1
• A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies — RECRUITING · PHASE1
• FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF THE BTK DEGRADER, ABBV-101, IN PARTICIPANTS WITH B-CELL MALIGNANCIES — RECRUITING
• A FIRST-IN-HUMAN MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF ABBV-319 IN B-CELL MALIGNANCIES — RECRUITING
• A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND -EXPANSION STUDY OF THE BRUTON TYROSINE KINASE TARGETED PROTEIN DEGRADER BGB-16673 IN PATIENTS WITH B-CELL MALIGNANCIES — RECRUITING · PHASE1
• A MULTICENTER, OPEN-LABEL, PHASE 2 BASKET STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK¿2140 AS A MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH AGGRESSIVE AND INDOLENT B-CELL MALIGNANCIES — RECRUITING · PHASE2
• A PHASE 1/2 DOSE ESCALATION AND COHORT EXPANSION STUDY OF THE SAFETY AND EFFICACY OF ALLOGENEIC CRISPR-CAS9-ENGINEERED T CELLS (CTX110) IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES — RECRUITING · PHASE1
• A PHASE 1/2A DOSE ESCALATION AND COHORT EXPANSION STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-LAG-3 MONOCLONAL ANTIBODY (BMS-986016) ADMINISTERED ALONE AND IN COMBINATION WITH ANTI-PD-1 MONOCLONAL ANTIBODY (NIVOLUMAB, BMS-936558) IN RELAPSED OR REFRACTORY B-CELL MALIGNANCIES — RECRUITING · PHASE1
• Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) — ACTIVE_NOT_RECRUITING · PHASE2
• Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised Patients — COMPLETED
• A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with Relapsed or Refractory B-Cell Malignancies (TITANium) — TERMINATED · PHASE1
• Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies — COMPLETED · PHASE1
• Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets — ACTIVE_NOT_RECRUITING · PHASE1
• Expression of CD274 (PD-L1) and CD276 in B-cell Malignancies: A Study by Flowcytometry — NOT_YET_RECRUITING
• A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies — NOT_YET_RECRUITING · PHASE1
• Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms — NOT_YET_RECRUITING
• Phase Ia/Ib Study of UBX-303061 in Subjects with Relapsed/Refractory B-Cell Malignancies — NOT_YET_RECRUITING · PHASE1
• Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection — NOT_YET_RECRUITING · PHASE1
• Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial) — NOT_YET_RECRUITING · PHASE1
• Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies — ACTIVE_NOT_RECRUITING · PHASE3
• An Open-Label, Multicenter, Phase I/II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Escalating Doses of Mosunetuzumab (BTCT4465A) as a Single Agent and Combined with Atezolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia — OTHER · PHASE2
• A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) — COMPLETED · PHASE1
• Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies — TERMINATED · PHASE1
• Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies — COMPLETED · PHASE1
• An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients. — NOT_YET_RECRUITING · PHASE1
• A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) — COMPLETED · PHASE1
• A PHASE 1/2,OPEN-LABEL,MULTICENTER, DOSE ESCALATION AND COHORT EXPANSION STUDY OF THE SAFETY AND EFFICACY OF ANTI-CD19 ALLOGENEIC CRISPR-CAS9-ENGINEERED T CELLS (CTX112) IN SUBJECTS WITH RELAPSED OR REFRACTORY B CELL MALIGNANCIES — NOT_YET_RECRUITING · PHASE1
• A PHASE 2, OPEN-LABEL, MULTICENTRE, BASKET STUDY EVALUATING THE SAFETY AND EFFICACY OF BREXUCABTAGENE AUTOLEUCEL IN ADULTS WITH RARE B-CELL MALIGNANCIES (ZUMA-25) — NOT_YET_RECRUITING · PHASE2
• Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies — OTHER · PHASE1
• Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies — COMPLETED · PHASE1
• A SINGLE ARM, OPEN-LABEL, PHASE 1B TRIAL OF EPCORITAMAB IN PEDIATRIC PATIENTS WITH RELAPSED/ REFRACTORY AGGRESSIVE MATUR B-CELL NEOPLASMS — COMPLETED · PHASE1
• A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies — COMPLETED · PHASE1
• Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib — TERMINATED
• Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies — OTHER · PHASE1
• Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma — COMPLETED · PHASE1

Refine this search